Champions Oncology Inc (NASDAQ:CSBR)’s share price hit a new 52-week high on Thursday . The company traded as high as $16.69 and last traded at $16.73, with a volume of 29797 shares traded. The stock had previously closed at $13.97.
A number of brokerages have weighed in on CSBR. Janney Montgomery Scott began coverage on Champions Oncology in a research report on Monday, July 9th. They set a “buy” rating on the stock. Zacks Investment Research raised Champions Oncology from a “hold” rating to a “strong-buy” rating and set a $12.00 price target on the stock in a research report on Monday, September 17th. Craig Hallum began coverage on Champions Oncology in a research report on Tuesday, July 17th. They set a “buy” rating and a $12.00 price target on the stock. Finally, ValuEngine raised Champions Oncology from a “hold” rating to a “buy” rating in a research report on Tuesday, June 5th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $11.33.
The stock has a market capitalization of $158.76 million, a price-to-earnings ratio of -103.00 and a beta of 0.12. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.73 and a quick ratio of 0.73.
Champions Oncology (NASDAQ:CSBR) last announced its quarterly earnings results on Thursday, September 13th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. Champions Oncology had a negative return on equity of 97.02% and a negative net margin of 1.63%. The firm had revenue of $6.23 million for the quarter, compared to the consensus estimate of $5.85 million. equities research analysts anticipate that Champions Oncology Inc will post 0.19 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Champions Oncology in the second quarter valued at approximately $104,000. Renaissance Technologies LLC grew its position in shares of Champions Oncology by 63.3% in the second quarter. Renaissance Technologies LLC now owns 100,600 shares of the biotechnology company’s stock valued at $638,000 after purchasing an additional 39,000 shares during the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of Champions Oncology in the second quarter valued at approximately $646,000. Perkins Capital Management Inc. acquired a new position in shares of Champions Oncology in the second quarter valued at approximately $653,000. Finally, Tocqueville Asset Management L.P. acquired a new position in shares of Champions Oncology in the second quarter valued at approximately $729,000. 38.52% of the stock is currently owned by institutional investors.
About Champions Oncology (NASDAQ:CSBR)
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Featured Article: Market Capitalization and Individual Investors
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.